Design, synthesis, and in vitro antitumor activity of 6-aryloxyl substituted quinazoline derivatives

Quinazoline derivatives are a class of important antitumor drugs known as small molecule inhibitors that include epidermal growth factor receptor (EGFR) inhibitors. Based on the structure of poziotinib, a series of 6-aryloxyl substituted quinazoline derivatives were designed and synthesized. The in vitro antitumor activities of the compounds were evaluated by the 3-(4,5-dimethyl-thiazol-2- yl)2,5-diphenyltetrazolium bromide (MTT) method using the human gastric cancer N87 (HER2), nonsmall-cell lung cancer H1975 $(EGFRT^{790M/L858R})$, and A549 (EGFRWT) cell lines. The most promising compound 4m exhibited potent antitumoral activities with $IC_{50}$ values of 6.3 nM and 7.5 nM for N87 and H1975 cell lines, respectively. Meanwhile, it was less potent against A549 cancer cells with an $IC_{50}$ value of 29.9 μM. The molecular docking results suggested that compound 4m has different binding modes to the wild-type and mutated EGFR.

PDF

___

1 Blackadar CB. Historical review of the causes of cancer. World Journal of Clinical Oncology 2016; 7 (1): 54-86.doi: 10.5306/wjco.v7.i1.54
2 Zhang Y, Rong DQ, Li BB, Wang YX. Targeting epigenetic regulators with covalent small-molecule inhibitors. Journal of Medicinal Chemistry 2021; 64 (12): 7900-7925. doi: 10.1021/acs.jmedchem.0c02055
3 Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012; 16 (1): 15-31. doi: 10.1517/14728222.2011.648617
4 Konkimalla VB, Mccubrey JA, Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate’s activity in cancer cells. Current Cancer Drug Targets 2009; 9 (1): 72-80. doi: 10.2174/156800909787314020
5 Martinelli E, Troiani T, Morgillo F, Piccirillo MC, Monaco K et al. Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. Targeted Oncology 2006; 1 (3): 123-129. doi: 10.1007/s11523-006-0022-5
6 Han TY, Guo M, Zhang TT, Gan MX, Xie CF et al. A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway. Oncotarget 2017; 8 (17): 28063-28073. doi: 10.18632/oncotarget.14188
7 Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine 2005; 353 (2): 172-187. doi: 10.1056/NEJMra044389
8 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007; 7 (3): 169-181. doi: 10.1038/nrc2088
9 Nadeem AM, Kausar S, Wang F, Zhao YJ, Cui HJ. Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for glioblastoma. Cells 2019; 8 (4): 350-361. doi: 10.3390/cells8040350
10 Chen LF, Fu WT, Zheng LL, Liu ZG, Liang G. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. Journal of Medicinal Chemistry 2018; 61 (10): 4290-4300. doi: 10.1021/acs. jmedchem.7b01310
11 Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. International Journal of Medicinal Chemistry 2014; 2014: 395637. doi: 10.1155/2014/395637
12 Anshul C, Chesta B. Recent advances of quinazolinone derivatives as marker for various biological activities. International Research Journal of Pharmacy 2013; 4 (3): 49-58. doi: 10.7897/2230-8407.04309
13 Le Y, Gan YY, Fu YH, Liu JM, Li W et al. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. Journal of Enzyme Inhibition and Medicinal Chemistry 2020; 35 (1): 555-564. doi: 10.1080/14756366.2020.1715389
14 Jin H, Dan HG, Rao GW. Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors. Heterocyclic Communications 2018; 24 (1): 1-10. doi: 10.1515/hc-2017-0066
15 Herbst RS, Fukuoka M, Baselga J. Gefitinib--a novel targeted approach to treating cancer. Nature Reviews Cancer 2004; 4 (12): 956-965. doi: 10.1038/nrc1506
16 Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 2010; 11 (6), 521-529. doi : 10.1016/S1470- 2045(10)70112-1
17 Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences 2008; 105 (6): 2070-2075. doi: 10.1073/pnas.0709662105
18 Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Molecular Cancer Therapeutics 2008; 7 (4): 874-879. doi: 10.1158/1535-7163. MCT-07-2387
19 Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology 2012; 13 (5): 539-548. doi: 10.1016/S1470-2045(12)70086-4
20 Zhao W, Yu DL, Chen Z, Yao WL, Yang J et al. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer Letters 2021; 519: 141-149. doi: 10.1016/j.canlet.2021.07.007
21 Kim HJ, Kim HP, Yoon YK, Kim MS, Lee GS et al. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2- amplified breast cancer cells. Anticancer Drugs 2012; 23 (3): 288-297. doi: 10.1097/CAD.0b013e32834e7d9b
22 Kim TM, Lee KW, Oh DY, Lee JS, Im SA et al. Phase 1 studies of Poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors. Cancer Research & Treatment Official Journal of Korean Cancer Association 2018; 50 (3): 835-842. doi: 10.4143/crt.2017.303
23 Giaccone G, Wang YS. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treatment Reviews 2011; 37 (6): 456-464. doi: 10.1016/j.ctrv.2011.01.003
24 Zhao BB, Xiao Z, Qi JG, Luo R, Lan Z et al. Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. European Journal of Medicinal Chemistry 2019; 163: 367-380. doi: 10.1016/j.ejmech.2018.11.069
25 Flanagan ME, Abramite JA, Anderson DP, Aulabaugh A, Dahal UP et al. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. Journal of Medicinal Chemistry 2014; 57 (23): 10072-10079. doi: 10.1021/jm501412a
26 Xia GX, Chen WT, Zhang J, Shao JA, Zhang Y et al. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. Journal of Medicinal Chemistry 2014; 57 (23): 9889-9900. doi: 10.1021/jm5014659
27 Grabe T, Lategahn J, Rauh D. C797S Resistance: The undruggable EGFR mutation in non-small cell lung cancer? ACS Medicinal Chemistry Letters 2018; 9 (8): 779-782. doi: 10.1021/acsmedchemlett.8b00314